Since PD-L1 plays an important role in the immunosuppressive TME of classical Hodgkin lymphoma, PD-1 inhibitors, such as nivolumab and pembrolizumab, have been tested in clinical trials and have shown to be effective in patients with classical Hodgkin lymphoma [107,108]. The gene discussed is CD274; the disease is classic Hodgkin lymphoma.